4/10/2024, 11:42:03 am

Investec remains bullish on Cipla, forecasts 12-13% growth in India pharma

Investec maintains a bullish stance on Cipla, expecting 12-13% sales growth in the Indian pharma market and clearance of its Goa plant by the US FDA in a few months, paving the way for the production of Abraxane, a key drug in Cipla's pipeline. Investec retains its 'buy' call with a price target of Rs 1,900, implying a 15% upside potential.